Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$196.37 USD

196.37
1,434,682

-0.45 (-0.23%)

Updated Oct 3, 2024 12:21 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (32 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

AbbVie Faces California Insurance Department Suit for Humira

AbbVie's (ABBV) shares fall on a lawsuit by California insurance department accusing it of giving illegal kickbacks to doctors for prescribing Humira.

    Pfizer's Skin Disease Candidates Positive in Mid-Stage Study

    Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study.

      The Zacks Analyst Blog Highlights: JPMorgan, Mastercard, AbbVie, CVS Health and Estee Lauder

      The Zacks Analyst Blog Highlights: JPMorgan, Mastercard, AbbVie, CVS Health and Estee Lauder

        Pharma/Biotech Stocks to Watch This Prostate Cancer Month

        Here we highlight a few companies that are focused on developing treatments for prostate cancer.

          Roche's Child Arthritis Drug's New Formulation Gets FDA Nod

          Roche (RHHBY) gets FDA approval for the subcutaneous formulation of Actemra for the treatment of active systemic juvenile idiopathic arthritis in patients aged two years or older.

            Mark Vickery headshot

            Top Stock Reports for JPMorgan, Mastercard & AbbVie

            Today's Research Daily features new research reports on 16 major stocks, including JPMorgan (JPM), Mastercard (MA) and AbbVie (ABBV).

              Should Value Investors Consider AbbVie (ABBV) Stock Now?

              Let's see if AbbVie Inc. (ABBV) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

                AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia

                AbbVie (ABBV) gets FDA approval to include MRD-negativity (undetectable disease) data from phase III MURANO study on the label of Venclexta.

                  Vertex Completes Enrollment in Triple Combination Studies

                  Vertex Pharmaceuticals (VRTX) completes enrollment in two phase III studies evaluating VX-659 triple combination regimen in CF patients. Data is expected in the fourth quarter of 2018.

                    Kinjel Shah headshot

                    Lilly, Teva, Pfizer & Others Await FDA Decisions in September

                    FDA grants approval to 34 new treatments this year so far.

                      Pfizer's Skin Disease Drug Gets Breakthrough Therapy Status

                      Pfizer's (PFE) investigational oral JAK3 inhibitor PF-06651600 gets Breakthrough Therapy designation from the FDA for alopecia areata.

                        Vertex Inks Reimbursement Agreement for Orkambi in Australia

                        Vertex Pharmaceuticals (VRTX) finalizes a reimbursement agreement with Australian government, which will improve the access to the drug.

                          Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus

                          Novartis (NVS) & AbbVie (ABBV) get cancer approvals. Merck (MRK) gets FDA nod for two new HIV medicines.

                            Kinjel Shah headshot

                            4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline

                            We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.

                              AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

                              AbbVie (ABBV) closed at $97.30 in the latest trading session, marking a -0.84% move from the prior day.

                                AbbVie's Imbruvica Combo Gets FDA Nod for Rare Lymphoma

                                AbbVie's (ABBV) cancer drug Imbruvica gets FDA approval for use in combination with Roche's Rituxan for Waldenstrom's macroglobulinemia (WM), a rare form of Non-Hodgkin's lymphoma.

                                  AbbVie (ABBV) Up 3.7% Since Last Earnings Report: Can It Continue?

                                  AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                    Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review

                                    The FDA granted priority review to the Bristol-Myers' (BMY) label expansion application for Empliciti seeking approval of the drug in combination with Pomalyst in multiple myeloma patients who are resistant to Revlimid.

                                      AbbVie Posts Positive Data on Elagolix for Uterine Fibroids

                                      AbbVie (ABBV) reports positive top-line results from a phase III extension trial on its investigational candidate Elagolix for treating uterine fibroids in women.

                                        Kalyan Nandy headshot

                                        Top Analyst Reports: Mastercard, AbbVie, Twenty-First Century Fox & More

                                        Today's Research Daily features updated research reports on 16 major stocks, including Mastercard (MA), AbbVie (ABBV) and Twenty-First Century Fox (FOXA).

                                          Mylan (MYL) Q2 Earnings and Revenues Miss, Guidance Cut

                                          Mylan is expected to loose ground after its second-quarter results miss estimates. The cut in guidance is disappointing as well.

                                            Pharma Stock Roundup: LLY, AGN Post Solid Q2 Results, ABBV's Elagolix Gets FDA Nod

                                            Earnings are in focus this week with Lilly (LLY), Allergan (AGN) and Glaxo (GSK) delivering strong Q2 numbers. AbbVie (ABBV) gains FDA approval for Elagolix.

                                              AbbVie's (ABBV) Q2 Earnings Beat Estimates, 2018 View Up

                                              AbbVie's (ABBV) Q2 earnings top estimates with revenues marginally beating the same. Revenues increase on strong sales growth of Humira, Imbruvica and Mavyret.

                                                Roche (RHHBY) 1H18 Revenues Up Y/Y on Solid New Drug Sales

                                                Roche's (RHHBY) performance in the first half is buoyed by solid strength in new drugs like Ocrevus. The increase in guidance is impressive as well.

                                                  AbbVie (ABBV) Beats Q2 Earnings and Revenue Estimates

                                                  AbbVie (ABBV) delivered earnings and revenue surprises of 1.01% and 0.04%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?